Kryger Capital’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Kryger Capital’s Portfolio IBER.U Stock Details IBER.U Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-385,240	Closed	-$3.86M	–	276
2021 Q4	$3.86M	Buy	+385,240	New	+$3.84M	0.22%	95

Other funds holding IBER.U

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.43B AUM 16.47% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Kryger Capital's IBER.U Position: Q1 2022 in Review

Kryger Capital sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q1 2022, closing a stake of 385,240 shares — an estimated $3.86M sold.

Kryger Capital first reported a position in IBER.U in Q4 2021 and held it in 1 quarter. The position peaked at $3.86M in Q4 2021. 18 funds tracked by Wall St. Rank hold IBER.U as of Q1 2022.

Kryger Capital reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q1 2022 after selling out during the quarter.
Kryger Capital sold 385,240 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q1 2022, an estimated $3.86M.
Kryger Capital first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q4 2021 and held it in 1 quarter.
Kryger Capital's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $3.86M in Q4 2021.
18 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q1 2022.

Based on Kryger Capital's 13F filing for Q1 2022, filed 12 May 2022.